Asthma Insurance Claim Denied in Indiana? Here's How to Appeal

Indiana's industrial manufacturing base, coal plant emissions, and high rates of smoking have created one of the Midwest's heaviest respiratory disease burdens. From Gary's steel industry air pollution to Indianapolis highway traffic, asthma and COPD patients across Indiana frequently face insurance denials for biologics and specialist care. Indiana law gives you the right to fight back.

Why Indiana Insurers Deny Asthma Claims

Common denial patterns in Indiana:

• Step therapy for biologics: Insurers require failure on multiple controller medications before approving Dupixent (dupilumab), Fasenra, Nucala, or Tezspire
• Dupixent prior auth barriers: Insurers claim patients don't meet eosinophil thresholds for Dupixent, ignoring the OCS-dependent indication that has no eosinophil minimum
• HIP 2.0 formulary barriers: Indiana's Medicaid alternative program (HIP 2.0) MCOs apply restrictive prior authorization for specialty biologics
• Nebulizer and DME denials: Home nebulizers denied as not medically necessary alongside inhaler prescriptions
• Rescue inhaler frequency limits: Albuterol restricted even for patients with documented frequent exacerbations
• Rural out-of-network denials: Northern and southern Indiana patients often have no accessible in-network pulmonologists

Indiana Insurance Regulator: IDOI

The Indiana Department of Insurance (IDOI) regulates commercial health insurers and administers External Independent Review: Complete Guide" class="auto-link">external review in Indiana.

IDOI Consumer Assistance:

• Phone: 1-317-232-2395
• Toll-free: 1-800-622-4461
• Website: in.gov/idoi
• File a complaint: in.gov/idoi/consumer-assistance

Indiana law provides for external review of adverse benefit determinations. External review decisions from certified IROs are binding on the insurer. Standard reviews are completed within 45 days; expedited reviews within 72 hours for urgent cases.

HIP 2.0 and Asthma Biologics in Indiana

HIP 2.0 (Healthy Indiana Plan) is Indiana's Medicaid expansion alternative, serving adults who don't qualify for traditional Medicaid. HIP 2.0 operates through managed care plans including Anthem, MDwise (Managed Health Services), and Physicians Health Plan of Northern Indiana.

HIP 2.0 coverage for asthma biologics requires prior authorization. Key aspects of HIP 2.0 that affect biologic coverage:

• POWER Account (HIPA): HIP 2.0's health savings account-like component — biologic costs often exceed POWER Account limits and fall into the plan benefit
• Formulary restrictions: Each MCO's formulary may be more restrictive than Indiana Medicaid itself requires
• Step therapy requirements: HIP 2.0 MCOs commonly require step therapy before approving biologics

For HIP 2.0 denials:

• File a grievance with your MCO within 60 days of denial
• Request a State Fair Hearing through FSSA: 1-800-403-0864
• Contact Indiana Legal Services: indianalegalservices.org for free legal assistance

Dupixent for Asthma: The Indiana Prior Auth Fight

Dupixent (dupilumab) is one of the most commonly denied biologics by Indiana commercial insurers and HIP 2.0 MCOs. The key argument in your favor:

Dupixent has two separate FDA indications for asthma:

1. Moderate-to-severe asthma with an eosinophilic phenotype (any level of eosinophils, not just high)
2. Oral corticosteroid-dependent asthma — this indication has no eosinophil minimum

If your insurer denies Dupixent citing low eosinophil counts but you are on oral steroids (prednisone, prednisolone) to control your asthma, cite the OCS-dependent indication explicitly. This is legally distinct from the eosinophilic indication, and insurers cannot require the same eosinophil threshold.

Your physician's letter should state: "This patient has OCS-dependent asthma requiring [X mg/day] prednisone-equivalent for asthma control, meeting FDA indications for dupilumab under the oral corticosteroid-dependent asthma indication, which does not require a minimum eosinophil threshold."

FDA-Approved Biologics: Building Your Indiana Appeal

• Dupixent (dupilumab): Eosinophilic or OCS-dependent asthma — two distinct indications
• Fasenra (benralizumab): Severe eosinophilic asthma (eosinophils ≥300 cells/μL)
• Nucala (mepolizumab): Severe eosinophilic asthma; COPD with eosinophilic phenotype
• Tezspire (tezepelumab): Uncontrolled severe asthma — no eosinophil minimum
• Xolair (omalizumab): Allergic asthma with documented IgE sensitization

Include eosinophil counts, IgE levels, OCS use history, spirometry, exacerbation records, and prior medication trials with documented outcomes.

Gary and Northwest Indiana: Industrial Asthma

Northwest Indiana — particularly Gary, East Chicago, and Hammond — has some of the worst air quality in the Midwest, driven by ArcelorMittal, BP Whiting Refinery, and other heavy industrial facilities. This industrial corridor sits adjacent to Chicago's south side, creating a cross-state air quality region with extreme asthma burdens. Indiana's Latino and Black communities in this region face disproportionate asthma hospitalizations.

Step-by-Step Appeal Process in Indiana

1. Get denial in writing: Full EOB and denial letter with specific clinical criteria
2. Internal appeal: File within 60–180 days; include physician letter specifically addressing the Dupixent OCS-dependent indication or applicable biologic indication
3. Peer-to-peer review: Physician contacts insurer's medical director
4. Step therapy exception: Formal request citing Indiana step therapy protections
5. IDOI external review: After internal appeal exhaustion; binding on insurer
6. IDOI complaint: in.gov/idoi/consumer-assistance — complaint triggers investigation

Indiana Advocacy Resources

• American Lung Association – Indiana: lung.org | 1-800-586-4872
• Indiana Legal Services: indianalegalservices.org — free legal help statewide
• Indiana State Department of Health Asthma Program: in.gov/isdh — asthma education resources
• Hoosier Environmental Council: hecweb.org — Northwest Indiana air quality advocacy
• NAACP Indiana: (local chapters in Indianapolis, Gary, Fort Wayne) — health equity advocacy

Fight Back With ClaimBack

Indiana asthma patients deserve better than being trapped in step therapy loops and denied access to FDA-approved treatments. ClaimBack helps you build an appeal that cites the correct FDA indication — including Dupixent's OCS-dependent indication — and invokes your rights under Indiana and federal law.

Start your appeal at ClaimBack — know your indication, fight your denial.

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied